Replicating poxviruses for human cancer therapy
Author:
- 8 April 2015
- journal article
- review article
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 53 (4) , 209-218
Abstract
Naturally occurring oncolytic viruses are live, replication-proficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the eradication of smallpox in the 1970s with the aid of vaccinia viruses, the vaccinia viruses and other genera of poxviruses have shown various degrees of safety and efficacy in pre-clinical or clinical application for human anti-cancer therapeutics. Furthermore, we have recently discovered that cellular tumor suppressor genes are important in determining poxviral oncolytic tropism. Since carcinogenesis is a multi-step process involving accumulation of both oncogene and tumor suppressor gene abnormalities, it is interesting that poxvirus can exploit abnormal cellular tumor suppressor signaling for its oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity/maintenance. Thus, tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects, which would in turn result in oncolytic virus susceptibility. This review outlines the characteristics of oncolytic poxvirus strains, including vaccinia, myxoma, and squirrelpox virus, recent progress in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and poxviral oncolytic tropism, and the associated preclinical/clinical implications. I would also like to propose future directions in the utility of poxviruses for oncolytic virotherapy.Keywords
This publication has 91 references indexed in Scilit:
- Evolutionary History and Attenuation of Myxoma Virus on Two ContinentsPLOS Pathogens, 2012
- Viral Vector-Based Therapeutic Cancer VaccinesThe Cancer Journal, 2011
- MicroRNA Regulation of Glycoprotein B5R in Oncolytic Vaccinia Virus Reduces Viral Pathogenicity Without Impairing Its Antitumor EfficacyMolecular Therapy, 2011
- Synergistic Interaction Between Oncolytic Viruses Augments Tumor KillingMolecular Therapy, 2010
- Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural PathogenicityMolecular Therapy, 2010
- Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumoursGene Therapy, 2009
- Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cellsLeukemia, 2009
- Vaccinia virus vaccines: Past, present and futureAntiviral Research, 2009
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Journal of Clinical Investigation, 2007
- Further characterization of raccoonpox virusArchives of Virology, 1975